Cargando…

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Hottinger, A F, Ben Aissa, A, Espeli, V, Squiban, D, Dunkel, N, Vargas, M I, Hundsberger, T, Mach, N, Schaller, K, Weber, D C, Bodmer, A, Dietrich, P-Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877431/ https://www.ncbi.nlm.nih.gov/pubmed/29315292 http://dx.doi.org/10.1038/bjc.2017.469

Ejemplares similares

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
por: Hottinger, A F, et al.
Publicado: (2014)

Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo
por: Rocha, C R R, et al.
Publicado: (2015)

Radiation and chemotherapy for high‐risk lower grade gliomas: Choosing between temozolomide and PCV
por: McDuff, Susan G. R., et al.
Publicado: (2019)

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer
por: Khan, O A, et al.
Publicado: (2009)

Corrigendum to “Intraoperative Contrast Enhanced Ultrasound Evaluates the Grade of Glioma”
por: Cheng, Ling-Gang, et al.
Publicado: (2017)

Temozolomide and Reirradiation in Recurrent Grade II Brain Glioma
por: Osman, Mohammed A
Publicado: (2014)

Temozolomide in paediatric high-grade glioma: a key for combination therapy?
por: Verschuur, A C, et al.
Publicado: (2004)

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
por: Cummins, K D, et al.
Publicado: (2014)

Natural borneol is a novel chemosensitizer that enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage [Corrigendum]
Publicado: (2018)

Corrigendum to “Simulating Radiotherapy Effect in High-Grade Glioma by Using Diffusive Modeling and Brain Atlases”
por: Roniotis, Alexandros, et al.
Publicado: (2018)

Depatux-M and temozolomide in advanced high-grade glioma
por: Hirsch, Sophie, et al.
Publicado: (2020)

Corrigendum to ‘Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells’[Redox Biol 6(2015):174–182]
por: Rodríguez-Hernández, A., et al.
Publicado: (2023)

Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033
por: Klein, Martin, et al.
Publicado: (2020)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum]
Publicado: (2021)

Corrigendum to “Downregulation of Thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer” [Redox Biol. 34 (2020) 101528]
por: González, R., et al.
Publicado: (2023)

CORRIGENDUM: Population Pharmacokinetics of Selumetinib and Its Metabolite N‐desmethyl‐selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low‐Grade Gliomas
Publicado: (2017)

Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy
por: Murphy, P S, et al.
Publicado: (2004)

Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Publicado: (2022)

In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
por: Ashley, D M, et al.
Publicado: (2009)

Effect of temozolomide on survival in elderly patients with glioblastoma and impaired performance status: a propensity score-matching analysis [Corrigendum]
Publicado: (2017)

Prediction of Response to Temozolomide in Low‐Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics
por: Mazzocco, P, et al.
Publicado: (2015)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Delayed but Complete Response following Oral Temozolomide Treatment in Melanoma Leptomeningeal Carcinomatosis
por: Hottinger, Andreas F., et al.
Publicado: (2011)

Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide
por: Koekkoek, Johan A. F., et al.
Publicado: (2015)

Temozolomide with Radiation Therapy in High Grade Brain Gliomas: Pharmaceuticals Considerations and Efficacy; A Review Article
por: Koukourakis, Georgios V., et al.
Publicado: (2009)

Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study [Corrigendum]
Publicado: (2013)

IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum]
Publicado: (2020)

Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy
por: Zhou, Xiaofeng, et al.
Publicado: (2016)

Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy
por: Guillevin, R, et al.
Publicado: (2011)

Corrigendum to “TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma” [EBioMedicine 40 (2019) 446–456]
por: Tan, Wenliang, et al.
Publicado: (2022)

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature
por: Jeck, Jennifer, et al.
Publicado: (2018)

High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers
por: Miyamoto, M, et al.
Publicado: (2017)

Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread
por: Marinari, Eliana, et al.
Publicado: (2021)

Corrigendum to “Synergistic Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide and Sorafenib against Cancer Stem Cells, Anaplastic Thyroid Cancer” [Neoplasia 19 (2017) 145-153]
por: Park, Ki Cheong, et al.
Publicado: (2017)

CIRP Regulates BEV-Induced Cell Migration in Gliomas [Corrigendum]
Publicado: (2020)

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways
por: Cleton-Jansen, A-M, et al.
Publicado: (2009)

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer
por: Koti, M, et al.
Publicado: (2015)

Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial
por: Gallia, Gary L, et al.
Publicado: (2020)

Efficacy and safety of long-term therapy for high-grade glioma with temozolomide: A meta-analysis
por: Xu, Weilin, et al.
Publicado: (2017)

ACT-18 SHOULD THE DOSE OF TEMOZOLOMIDE BE DECREASED FOR PATIENTS WITH HIGH-GRADE GLIOMAS WHO ARE ON HEMODIALYSIS?
por: Muto, Jun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tt0egnaljhcknu9q78v2j5gg43